Recently, Jorgensen et al. described a shift from an epithelial to a mesenchymal (or intermediate) phenotype from primary tumors to recurrences based on the expression levels of EMT markers such as E-cadherin, vimentin, Twist, and N-cadherin in breast cancer [73]. This evidence concerns the gene CDH2 and breast cancer.